As contemporary surgical practice continues to evolve, patients who undergo surgical lung volume reduction (LVRS) for ...

The advantage of the GOLD guidelines is that they gave the physicians specific goals in diagnosing and treating patients with COPD ... decide on pharmacological treatment for each group.

While COPD is not curable, it is a preventable and treatable illness. The earlier you start treatment, the better your prognosis ... chronic bronchitis (irritation of the bronchial tubes) and ...

To help with COPD flare-ups, you may consider a medication inhaler, antibiotics, oxygen therapy, and hospital care. Your healthcare team can best advise you on treatment for COPD exacerbations.

COPD was judged to be included in the study if one of the following three items were met. As follows: 1. FEV1/FVC <0.7 after inhaled bronchodilators. 2. Have you been diagnosed with emphysema in the ...

(Photo: CNA/Lim Li Ting) New: You can now listen to articles. SINGAPORE: Guidelines on screen use will be introduced in schools, including preschools, as part of a new national strategy launched ...

Chronic obstructive pulmonary disease (COPD) can result from chronic bronchitis or emphysema ... symptoms usually worsen over time without treatment. You can also develop conditions like irregular ...

COPD comprises several conditions, including chronic bronchitis and emphysema, and can be caused by genetics and irritants like smoke or pollution. Symptoms include breathlessness, fatigue ...

Chronic lower respiratory diseases, including chronic obstructive pulmonary disease (COPD), are the sixth leading cause of death in the United States, according to the U.S. Centers for Disease Control ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Emphysema is a long-term lung condition that causes shortness of breath, according to the Mayo Clinic. It is a type of chronic obstructive pulmonary disease (COPD). "Over time, the condition ...

UK pharma major AstraZeneca’s (LSE: AZN) Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 JP Morgan Healthcare Conference, is set to transform the chronic ...